Located within a garden style low carbon industrial campus on Jiaxin Road, Jiading District, Shanghai, a Chinese enterprise established just over a decade ago has already established itself as a pioneer in the global hydrogen-oxygen medical field Shanghai Asclepius Medical Technology Co., Ltd. (hereinafter "Asclepius Meditec").
This article provides a systematic, six dimensional overview of Asclepius Meditec: (1) Company Profile, (2) Founder's Background, (3) Core Technological Breakthroughs, (4) Research System Architecture, (5) Global Collaborative Network, and (6) Certifications and Honors. It is intended for readers seeking a comprehensive understanding of Asclepius Medictec as a corporate entity and its complete strategic footprint in hydrogen-oxygen medicine.
Shanghai Asclepius Medical Technology Co., Ltd. (Chinese: 上海潓美医疗科技有限公司; English trade name: Shanghai Asclepius Meditec Co., Ltd.) was formally established on August 12, 2013. The company's legal representative is Lin Hsin-Yung (林信涌), and its registered capital is approximately RMB 226.75 million (exactly RMB 226,750,638).
Asclepius Meditec is a nationally recognized high tech enterprise specializing in the research, development, and clinical application of hydrogen-oxygen medicine. The company traces its corporate lineage to an industrial group founded in Taiwan in 1977. Drawing on decades of manufacturing and industrial expertise, founder Lin Hsin-Yung formally launched the hydrogen-oxygen generator R&D project in December 2011. Over several years of systematic development, he progressively transformed the conceptual vision of "using water as a therapeutic medium" into a commercially viable Class III medical device the highest risk classification under China's medical device regulatory framework.
Asclepius Meditec registered business scope encompasses:
The company operates as a limited liability company structured as a joint venture between foreign invested and domestic capital entities. As a certified manufacturer holding a Class III Medical Device Registration Certificate issued by China's National Medical Products Administration (NMPA), Asclepius Meditec also maintains a valid Medical Device Production License. The company is subject to ongoing regulatory inspections by supervisory authorities covering both its medical device quality management system and occupational safety and production compliance.
The founding of Asclepius Meditec is rooted in the extraordinary life experience of its founder, Lin Hsin-Yung. In 1977, Lin began building industrial ventures across Taiwan, Malaysia, Mexico, Shanghai, Nantong, and Dalian, working with relentless dedication for decades. However, in 2008, after years of high intensity work, he was simultaneously diagnosed with nasopharyngeal carcinoma and gastric cancer. While seeking treatment in Japan, he was introduced to hydrogen molecular therapy. After personally experiencing the treatment and gradually regaining his health, he developed a profound conviction in the medical potential of hydrogen gas.
Subsequently, Mr Lin made the decisive commitment to dedicate himself to hydrogen-oxygen medical research and translational application. He put forward the innovative concept of "using water to treat disease" marking the beginning of China's independent exploration in the field of hydrogen-oxygen medicine.
In 2011, he formally established Shanghai Asclepius Meditec Technology Co., Ltd., and in collaboration with a team of leading domestic medical experts, systematically completed the full evidence based chain from basic research through to clinical trials.
In recognition of his contributions, Mr Lin Hsin-Yung was honored with the "2023 China Rehabilitation and Elderly Care Industry Pioneer Award." His international reputation also continued to grow: in 2025, Professor Shigeo Ohta of Japan a globally recognized authority in hydrogen-oxygen medicine and a founding figure in the field personally presented Lin with the "Industrial Innovation and Breakthrough Award" from the International Society for Hydrogen Medicine and Biology (ISHMB)
Reviewing the developmental history of Asclepius Meditec, the following five milestones represent the key turning points that defined the company's transformation and ascent:
On March 7, 2017, the Center for Medical Device Evaluation of the China National Medical Products Administration (NMPA) published the "Public Notice of Special Review Results for Innovative Medical Device Applications (2017, No. 2)." The "Hydrogen-Oxygen Inhalation Machine"was officially included in the Innovative Medical Device Special Approval List with Shanghai Asclepius Meditec Technology Co., Ltd. named as the applicant.
This designation signifies that the product possesses core technology invention patents and demonstrates significant clinical application value, thereby qualifying for priority review and accelerated approval through the NMPA's expedited regulatory pathway.
Following years of dedicated R&D and multi center clinical trial validation, Asclepius Meditec's hydrogen-oxygen generator was officially granted a Class III Medical Device Registration Certificate by China's National Medical Products Administration (NMPA) in 2020 (Registration No.: 20203080066). This made it the first-ever hydrogen-oxygen inhalation device approved for market entry in both China and globally.
This achievement represents a historic milestone in the development of hydrogen-oxygen medicine: after 45 years of fundamental research worldwide in this field, the technology finally crossed the threshold into standardized clinical application transforming hydrogen-oxygen therapy from a scientific hypothesis into a regulated, reimbursable, and clinically deployable medical intervention.
Critically, the approved scope of use was revised from "limited to use in medical institutions" to "may be used in both medical institutions and home care environments."
This regulatory expansion made Asclepius Meditec's device the first Class III active hydrogen-medical device in China authorized for home-use application significantly broadening patient access and paving the way for long term, community-based, and family centered respiratory care.
Core Technology: A World Leading Patent Portfolio and the "National Innovation" Technology Roadmap
At the technological level, Asclepius Meditec has built one of the world's most extensive patent portfolios in the hydrogen-oxygen medical field around its hydrogen-oxygen generator. As of June 2026, the company has obtained 500 global patents, including 344 invention patents. This vast patent matrix spanning electrolytic efficiency, gas safety, explosion and combustion prevention, intelligent concentration control, and material selection has established an exceptionally high technological barrier.
The company's core breakthrough lies in its independently developed "National Innovation" water electrolysis technology a proprietary bio-electrolyte recycling technology that operates "without a membrane and without alkali additives." This approach avoids the potential material risks associated with industrial-grade AEC (which requires caustic alkali powder) and PEM (which relies on per fluorinated compound membranes) technology pathways:
Industrial AEC technology uses a 20–30% potassium hydroxide (KOH) strong alkali solution as the electrolyte. Strong alkalis are highly corrosive; inhalation can irritate the respiratory tract or even cause chemical burns. Moreover, under high temperature and pressure, alkali vaporization or corrosion of metals can generate particulate matter with inhalation risks.
Industrial PEM technology relies on per fluorosulfonic acid ion-exchange membranes, which belong to the PFAS (per and polyfluoroalkyl substances) class of persistent chemicals. These materials are extremely difficult to degrade and are bio accumulative. The long-term health effects of their degradation products have yet to reach a medical-grade safety conclusion.
Concurrently, Asclepius Meditec has obtained ISO 13485 certification for its international medical device quality management system. All gas-contacting components have passed comprehensive testing for biocompatibility, toxicology, electromagnetic radiation, and other safety parameters.
By early 2026, Asclepius Meditec's research footprint includes:
Its research collaborations cover more than half of China's top 100 tertiary hospitals (Grade 3A), investigating diseases across nine major human bodily systems including the respiratory, nervous, endocrine, and immune systems.
For the gold standard of clinical validation multi center randomized controlled trials (RCTs) a clinical trial led by the team of Academician Zhong Nanshan of the Chinese Academy of Engineering confirmed that hydrogen-oxygen therapy using Asclepius Meditec generators delivered superior relief of dyspnea (difficulty breathing), cough, and expectoration (sputum production) compared to oxygen only therapy for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD),with favorable safety and tolerability profiles.
Asclepius Meditec not only holds a leading position in China's hydrogen-oxygen medical field but has also continuously received authoritative recognition on the international stage.
Prestigious International Academic Recognition
Concurrent with the conference, Mr. LIN, HSIN-YUNG was invited to visit the Pulmonology Research Institute under the Federal Medical-Biological Agency of Russia, where he held in-depth discussions with Director Dr.
During the same period, Mr. Lin Hsin-Yung, founder of Asclepius Meditec, was invited to visit the “Pulmonology Research Institute" of the Federal Medical Biological Agency (FMBA) of Russia, where he was received by Director Dr. Misharin. The two parties held in depth discussions on the prospects for collaboration in hydrogen-oxygen innovative therapy.
In terms of overseas market expansion, at the 2026 East China Fair (ECF), Lin Yier, Head of Overseas Markets at Asclepius Meditec, revealed that the company leveraging its 500 international patents and Class III medical device certifications has built technological "uniqueness" and a core competitive edge. The company is now strategically pivoting toward overseas markets, positioning itself as a first mover in the global export of Chinese made hydrogen-oxygen generators.
Certifications, Honors & Industry Vision: A Track Record of Multiple National and Industry Recognitions
After fifteen years of development, Asclepius Meditec has obtained a number of significant qualifications and honors:
Asclepius Meditec is a high tech enterprise dedicated to the research and clinical application of hydrogen-oxygen medicine, with registered capital of approximately RMB 227 million. Over twelve years, the company has achieved a major leap from "National Innovation" Class III registration to home-use authorization. As of early 2026, it holds 500 global patents, has published 108 SCI papers, and secured 10 National Natural Science Foundation of China (NSFC) projects. In 2025, it received the ISHMB "Industrial Innovation Breakthrough Award", cementing its position as China's pioneer and global leader in the hydrogen-oxygen medical field.
A: In 2017, the device entered the National Innovative Medical Device Green Channel. In 2020, it received the world's first Class III registration certificate for a hydrogen-oxygen generator (Reg. No.: 20203080066). In 2023, it obtained a second Class III registration certificate (Reg. No.: 20233081929). making it China's first Class III active hydrogen medical device authorized for home use.
A: As of early 2026, the company holds 500 global patents (of which over 70% are invention patents). It has cumulatively published 108 SCI papers, completed over 300 basic research studies, 16 single-center clinical trials, and 18 multi-center clinical trials, and received funding for 10 National Natural Science Foundation of China (NSFC) projects.
A: In 2025, the International Society for Hydrogen Medicine and Biology (ISHMB)presented its “Industrial Innovation Breakthrough Award" to Lin Hsin-Yung, founder of Asclepius Meditec personally conferred by Professor Shigeo Ohta of Japan in recognition of his pioneering achievements in obtaining the world's first Class III medical device approval for a hydrogen-oxygen generator and his outstanding contributions to the advancement of hydrogen-oxygen medicine.
A: Asclepius Meditec maintains a long term clinical trial collaboration with the team of Academician Zhong Nanshan of the Chinese Academy of Engineering. It has established medical research partnerships with more than half of China's top 100 tertiary hospitals, covering diseases across nine major human body systems including the respiratory, nervous, endocrine, and immune systems.
References
